Citigroup Business Sale Proceeds increased by 513.2% to $233.00M in Q1 2026 compared to the prior quarter.
An increase signals portfolio optimization or a strategic pivot, while a lack of proceeds suggests a stable, long-term asset base.
This metric represents the cash inflows received from the divestiture or sale of business segments, product lines, or su...
Occurs sporadically; peers often divest legacy segments to focus on high-margin innovation areas like continuous glucose monitoring or diagnostics.
proceeds_from_sale_of_business| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$10.00M | $0.00 | $0.00 | $15.00M | $1.93B | $1.30B | $2.50B | $6.00M | -$6.00M | $0.00 | $56.00M | $162.00M | $12.00M | $27.00M | $21.00M | $0.00 | $16.00M | $8.00M | $38.00M | $233.00M |
| QoQ Change | — | +100.0% | — | — | >999% | -32.4% | +91.9% | -99.8% | -200.0% | +100.0% | — | +189.3% | -92.6% | +125.0% | -22.2% | -100.0% | — | -50.0% | +375.0% | +513.2% |
| YoY Change | — | — | — | — | >999% | — | — | -60.0% | -100.3% | -100.0% | -97.8% | >999% | +300.0% | — | -62.5% | -100.0% | +33.3% | -70.4% | +81.0% | — |